Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp demonstrates a positive financial outlook, underscored by its stock price rising approximately 4% following recent news, reflecting market confidence. The company is viewed as undervalued, trading at around 14 times net cash, which suggests a favorable risk/reward profile as it moves through pivotal phases of drug development and potential regulatory approval. Management's successful resolution of production observations at the contract development and manufacturing organization (CDMO) facility, alongside promising Phase 3 SAPPHIRE data, enhances the prospect of regulatory approval and market expansion in the spinal muscular atrophy (SMA) space, indicating significant upside potential.

Bears say

Scholar Rock Holding Corp faces a negative outlook primarily due to the delayed launch of its lead product, apitegromab, which has resulted in lowered peak sales estimates, now projected at $1.7 billion by 2035, due to competitive risks and the establishment of new standards of care. The company has been required to push back the commercial launch dates for both the US and EU, extending timelines significantly, which reflects an operational setback and increased regulatory scrutiny following the issuance of a Complete Response Letter (CRL) from the FDA. Furthermore, continued challenges related to the SRK-181 program and heightened competitive and regulatory risks for apitegromab illustrate an uncertain market position that could negatively impact revenue growth and investor confidence moving forward.

SRRK has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 9 analysts, SRRK has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.